# Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis

> **NCT06798415** · PHASE2 · RECRUITING · sponsor: **Hayder Adnan Fawzi** · enrollment: 40 (estimated)

## Conditions studied

- Cutaneous Leishmaniasis

## Interventions

- **DRUG:** Metronidazole

## Key facts

- **NCT ID:** NCT06798415
- **Lead sponsor:** Hayder Adnan Fawzi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-10
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06798415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06798415, "Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06798415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*